| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | 0.094 | 0.6 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.6 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.032 | 0.6 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | 0.031 | 0.6 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |